Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients ≥60 years (CALGB 9720)

被引：0
|
作者：
Baer, Maria R. [1 ]
George, Stephen L. [1 ]
Sanford, Ben L. [1 ]
Bothun, Sandra M. [1 ]
Mrozek, Krzysztof [1 ]
O'Loughlin, Kieran L. [1 ]
Kolitz, Jonathan E. [1 ]
Moore, Joseph O. [1 ]
Stone, Richard M. [1 ]
Powell, Bayard L. [1 ]
Caligiuri, Michael A. [1 ]
Bloomfield, Clara D. [1 ]
Larson, Richard A.
机构：
[1] Canc & Leukemia Grp B, Chicago, IL USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.296.296
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
296
引用
收藏
页码：94A / 94A
页数：1
相关论文
共 50 条
  • [1] Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
    M R Baer
    S L George
    B L Sanford
    K Mrózek
    J E Kolitz
    J O Moore
    R M Stone
    B L Powell
    M A Caligiuri
    C D Bloomfield
    R A Larson
    [J]. Leukemia, 2011, 25 : 800 - 807
  • [2] Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
    Baer, M. R.
    George, S. L.
    Sanford, B. L.
    Mrozek, K.
    Kolitz, J. E.
    Moore, J. O.
    Stone, R. M.
    Powell, B. L.
    Caligiuri, M. A.
    Bloomfield, C. D.
    Larson, R. A.
    [J]. LEUKEMIA, 2011, 25 (05) : 800 - 807
  • [3] Induction and consolidation therapy with intermediate-dose cytarabine, mitoxantrone and etoposide in patients >=60 years with acute myeloid leukemia (AML).
    Shepherd, JD
    Barnett, MJ
    Brockington, DA
    Fung, HC
    Klingemann, HG
    Nantel, SH
    Reece, DE
    Sutherland, HJ
    Thierman, JG
    Toze, CL
    Phillips, GL
    [J]. BLOOD, 1995, 86 (10) : 2075 - 2075
  • [4] Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
    Krogh-Madsen, Mikkel
    Bender, Brendan
    Jensen, Morten Krogh
    Nielsen, Ove Juul
    Friberg, Lena E.
    Honore, Per Hartvig
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1155 - 1163
  • [5] Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
    Mikkel Krogh-Madsen
    Brendan Bender
    Morten Krogh Jensen
    Ove Juul Nielsen
    Lena E. Friberg
    Per Hartvig Honoré
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 69 : 1155 - 1163
  • [6] Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (pts) ≥60 years (CALGB 9720).
    Baer, MR
    George, SL
    Dodge, RK
    Cooke, K
    Caligiuri, MA
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 1999, 94 (10) : 383A - 383A
  • [7] Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study
    Garg, Arun
    Ganguly, Shuvadeep
    Vishnubhatla, Sreenivas
    Chopra, Anita
    Bakhshi, Sameer
    [J]. PEDIATRIC BLOOD & CANCER, 2020, 67 (09)
  • [8] Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
    Murphy, Tracy
    Yee, Karen W. L.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (16) : 1765 - 1780
  • [9] Therapy of acute myeloid leukemia in patients over 60 years of age with intermediate dose cytarabine, mitoxantrone, and etoposide.
    Shepherd, JD
    Nantel, SH
    Toze, CL
    Hogge, DE
    Sutherland, HJ
    Conneally, EA
    Nevill, TJ
    Horsman, DE
    Makhija, S
    Thierman, JG
    Barnett, MJ
    [J]. BLOOD, 1999, 94 (10) : 237B - 237B
  • [10] Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502
    Attar, Eyal C.
    Johnson, Jeffrey L.
    Amrein, Philip C.
    Lozanski, Gerard
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Kolitz, Jonathan E.
    Powell, Bayard L.
    Voorhees, Peter
    Wang, Eunice S.
    Blum, William
    Stone, Richard M.
    Marcucci, Guido
    Bloomfield, Clara D.
    Moser, Barry
    Larson, Richard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 923 - 929
12345